1W Return
1M Return
6M Return
1Y Return
3Y Return
Start SIP in Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Stock Performance
52 Week Low - High
Today’s Low - High
Open
Prev. Close
Total Traded Value
Jagsonpal Pharmaceuticals Fundamental
Market Cap (in crs)
Face Value
Turnover (in lacs)
Key Metrics
Qtr Change %
31.42% Fall from 52W High
-6.7
Dividend yield 1yr %
Below industry Median
0.9
Jagsonpal Pharmaceuticals Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
Current Price
5Day EMA
228.90
10Day EMA
227.40
12Day EMA
226.60
20Day EMA
224.10
26Day EMA
223.20
50Day EMA
223.40
100Day EMA
222.30
200Day EMA
208.80
5Day SMA
233.10
10Day SMA
228.50
20Day SMA
221.90
30Day SMA
220.10
50Day SMA
218.70
100Day SMA
234.20
150Day SMA
225.70
200Day SMA
207.70
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 44201 Rs | 175051 Rs |
Week Rs | 149496 Rs | 1073069 Rs |
Month Rs | 77218 Rs | 365513 Rs |
Resistance & Support
226.62
Pivot
Resistance
First Resistance
231.18
Second Resistance
237.41
Third Resistance
241.97
Support
First Support
220.39
Second support
215.83
Third Support
209.60
Relative Strength Index
51.20
Money Flow Index
87.13
MACD
3.36
MACD Signal
2.19
Average True Range
13.51
Average Directional Index
20.24
Rate of Change (21)
6.59
Rate of Change (125)
24.67
Similar stocks
Similar Stocks
Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,493.44 | 110 | 328.04 | 227.46 | 0.40% | 3.57% | 7.81% | 55.55% | 84.82% | 0.88% | 41.02 | 40.74 | 7.58 | ||
1,251.90 | 92.15 | 185.5 | 123.09 | -4.72% | 0.87% | -5.68% | -3.88% | 47.50% | 0.42% | 15.45 | 40.74 | 1.22 | ||
1,189.80 | 115 | 317 | 130.96 | -6.04% | -12.05% | -50.01% | -41.43% | 40.02% | 0.39% | 31.82 | 40.74 | 4.08 | ||
1,516.69 | 1242.95 | 3379 | 1,838.10 | -1.41% | 42.12% | -25.21% | 8.36% | -31.76% | 0.34% | 51.34 | 40.74 | 4.68 | ||
Syncom Formulation (India) Ltd. | 16.32 | - | - | - | - | - | - | - | - | - | - | - | - | |
1,393.14 | 34 | 75.5 | 43.55 | -6.03% | 18.73% | -14.67% | -37.92% | 42.79% | 0.24% | 26.64 | 40.74 | 3.11 | ||
Remus Pharmaceuticals Ltd. | 2,020.40 | - | - | - | - | - | - | - | - | - | - | - | - |
Jagsonpal Pharmaceuticals Company background
Founded in: 1978
Managing director: Manish Gupta
Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously, it has geared up to set up an ultra modern multipurpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.The company has a strategic alliance with Fidia Spa, Italy and B Spofola, Czechoslovakia to manufacture sophisticated drugs in India. It has tied up with another Israelbased company, Makhteshim Chemical Works, for acquiring the marketing rights of an antioxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.The Companys RD activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. Its RD activities are geared towards development of new product technologies which can be commercialised in future.It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.In the fiscal 2001, the companys sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.On June 27, 2022, Infinity Holdings, an Indiafocused investment group acquired control over the Company consequent to acquisition of 43.73% of equity capital and became Promoters of the Company. The Company identified several products as part of new launches such as Indocap Gel, Lycored Plus, MemUp, Queezy ER to enhance healthcare professionals confidence and improve patient outcomes in 202324. It acquired the India and Bhutan business of Yash Pharma in May, 2024.
Jagsonpal Pharmaceuticals FAQs
What is Share Price of Jagsonpal Pharmaceuticals ?
Jagsonpal Pharmaceuticals share price is ₹223.01 in NSE and ₹225.2 in BSE as on 30/4/2025.
How has Jagsonpal Pharmaceuticals shares performed in the past ?
Jagsonpal Pharmaceuticals share price in the past 1-year return was 55.55. The Jagsonpal Pharmaceuticals share hit a 1-year low of Rs. 110 and a 1-year high of Rs. 328.04.
What is the market cap of Jagsonpal Pharmaceuticals ?
The market cap of Jagsonpal Pharmaceuticals is Rs. 1493.44 Cr. as of 30/4/2025.
What is the current P/E ratio of Jagsonpal Pharmaceuticals ?
The PE ratios of Jagsonpal Pharmaceuticals is 41.02 as of 30/4/2025.
What is the current PB ratio of Jagsonpal Pharmaceuticals ?
The PB ratios of Jagsonpal Pharmaceuticals is 7.58 as of 30/4/2025
How to buy Jagsonpal Pharmaceuticals shares?
You can easily buy Jagsonpal Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
Please be aware that Jagsonpal Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account
